John Eikelboom

Oct 5, 2024 | onlinelibrary.wiley.com | Nauzer Forbes |Jackie Bosch |John Eikelboom

Dear Editors, We thank Dr. Yang et al. for their interest in our study [1]. In their letter [2], they suggested that our analysis of the incidence and predictors of major gastrointestinal bleeding in patients on aspirin 100 mg once daily, rivaroxaban 5 mg twice daily or the combination of aspirin 100 mg once daily and rivaroxaban 2.5 mg twice daily had ‘critical’ limitations [1]. First, they suggested that we ‘neglected’ to report long-term outcomes after major acute bleeding.

Aug 20, 2024 | onlinecjc.ca | Darryl Leong |Jackie Bosch |John Eikelboom

In their insightful comments on our analysis 1 Leong D.P. Bosch J. Bhatt D.L. et al. Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial.

Jul 11, 2024 | onlinecjc.ca | John Eikelboom |William F McIntyre |William Mcintyre |Jacqueline Bosch |Richard P. Whitlock |Qilong Yi | +6 more

Abstract Win ratio (WR) is a newer analytic approach for trials with composite endpoints that accounts for the relative importance of individual components. Our objective was to compare the results of the COMPASS trial analysed using WR compared with conventional statistical approaches.

Jun 22, 2024 | onlinecjc.ca | Darryl Leong |Jackie Bosch |São Paolo |John Eikelboom

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Mar 20, 2024 | nature.com | Azita H. Talasaz |Parham Sadeghipour |John Eikelboom |Deborah M. Siegal |Manuel Monreal |David Jimenez | +8 more

AbstractBalancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for interference with the absorption of antithrombotic drugs and for an increased risk of bleeding. In this Review, we address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities.